Tyra Biosciences (NASDAQ:TYRA) Stock Gets Price Target Trim from HC Wainwright

Tyra Biosciences (NASDAQ:TYRA) had its target price decreased by equities research analysts at HC Wainwright from $29.00 to $27.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price objective suggests a potential upside of 28.57% from the company’s current price.

A number of other analysts have also issued reports on the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $50.00 price target on shares of Tyra Biosciences in a research report on Tuesday, October 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tyra Biosciences in a research report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Thursday, October 15th. Wedbush reiterated an “outperform” rating and issued a $53.00 price objective on shares of Tyra Biosciences in a research note on Thursday, September 10th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $56.00 target price on shares of Tyra Biosciences in a research report on Tuesday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

Tyra Biosciences Trading Down 5.8%

NASDAQ:TYRA opened at $21.00 on Wednesday. The business’s fifty day moving average price is $22.04 and its 200 day moving average price is $29.54. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -8.75 and a beta of 0.65. Tyra Biosciences has a 1-year low of $13.83 and a 1-year high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07). Equities analysts forecast that Tyra Biosciences will post -2.68 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Alps Advisors Inc. raised its stake in shares of Tyra Biosciences by 31.4% during the 3rd quarter. Alps Advisors Inc. now owns 79,051 shares of the company’s stock worth $1,729,000 after purchasing an additional 18,892 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Tyra Biosciences during the 3rd quarter valued at about $67,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Tyra Biosciences by 15.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,889 shares of the company’s stock valued at $239,000 after buying an additional 1,424 shares during the last quarter. Sterling Capital Management LLC grew its stake in shares of Tyra Biosciences by 843.4% in the 3rd quarter. Sterling Capital Management LLC now owns 1,217 shares of the company’s stock valued at $27,000 after buying an additional 1,088 shares in the last quarter. Finally, Tidal Investments LLC bought a new stake in shares of Tyra Biosciences in the 2nd quarter valued at approximately $943,000. 84.14% of the stock is owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.